Alzamend Neuro Inc reports results for the quarter ended in April - Earnings Summary

Alzamend Neuro

31/07/2024 24:13

* Alzamend Neuro Inc  ALZN.OQ  reported a quarterly adjusted
loss
of $13.35​​ per share for the quarter ended in April, lower than
the same quarter last year, when the company reported EPS of
$-4.50.  The mean expectation of two analysts for the quarter
was for a loss of $2.75 per share. Wall Street expected
results to range from $-3.80 to $-1.70 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Alzamend Neuro Inc's reported EPS for the quarter was a
loss of
$13.35​.
    * The company reported a quarterly loss of $851.53 thousand.
    * Alzamend Neuro Inc shares had risen by 1.2% this
quarter and
lost 55.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "hold."

Wall Street's median 12-month price target for Alzamend Neuro
Inc is $210.00 
This summary was machine generated from LSEG data July 30 at
11:13 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Apr. 30 2024      -2.75          -13.35         Missed
 Jan. 1 0001       -3.25          -3.80          Missed
 Oct. 31 2023      -6.75          -4.40          Beat
 Jul. 31 2023      -5.25          -6.00          Missed